IPMN
11
1
3
2
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 49/100
9.1%
1 terminated out of 11 trials
66.7%
-19.8% vs benchmark
0%
0 trials in Phase 3/4
50%
1 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (11)
Genomic Resources for Enhancing Available Therapies (GREAT1.0) Study
Surveillance Discontinuation in 5 Year Stable Trivial Branch Duct Intraductal Papillary Mucinous Neoplasms
The Prevention of Progression to Pancreatic Cancer Trial (The 3P-C Trial)
Impact of GLP-1 Receptor Agonists on Patients With IPMN
Intraductal Papillary Mucinous Neoplasm (IPMN) Database - A Tool to Predict Pancreatic Cancer
Feasibility of Molecular Biology in Pancreatic Cyst Tumors
Pancreatic Cancer and Oral Microbiome
TOF-18F-FDG-PET/CT in Patients With Suspected Pancreatic Cancer
Utility of EUS-guided Microbiopsies in Pancreatic Cystic Lesions
Quality of Life Assessment in Patients Who Are Under Surveillance for IPMN
Intraductal Papillary Mucinous Neoplasm With Malignant Change